title: [A case of intragastric wall abscess formation during bevacizumab combined chemotherapy].
abstract: A 38-year-old man was given a diagnosis of as sigmoid colon cancer and underwent sigmoid colectomy. Post-operative pathological staging was stage IIIb. He then underwent adjuvant chemotherapy. One year and 4 months after the surgery, CT scans revealed multiple liver and lung metastases. He was given mFOLFOX6+bevacizumab, which was changed later to FOLFIRI+bevacizumab. After these chemotherapies, he was admitted to the hospital due to sudden abdominal pain and high grade fever. Obstructive jaundice was initially diagnosed, but detailed study of initial CT revealed intragastric wall abscess. After the drainage of the abscess, his conditions improved. We speculated that the abscess formation was caused by mucosal damage due to bevacizumab.
authors: Department of Medical Oncology, Tonan Hospital, Japan. a-mori@tonan.gr.jp
authors: Ayano
authors: A
authors: Mori
authors: Takahiro
authors: T
authors: Kogawa
authors: Youhei
authors: Y
authors: Arihara
authors: Masakazu
authors: M
authors: Abe
authors: Fumito
authors: F
authors: Tamura
authors: Seiichirou
authors: S
authors: Abe
authors: Takehiro
authors: T
authors: Kukitsu
authors: Hideyuki
authors: H
authors: Ihara
authors: Tetsuya
authors: T
authors: Sumiyoshi
authors: Naoto
authors: N
authors: Yoshizaki
authors: Hitoshi
authors: H
authors: Kondou
authors: Yasushi
authors: Y
authors: Tsuji
mesh_terms: D000038:Abscess / Q000139:chemically induced*; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D000068258:Bevacizumab; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D005753:Gastric Mucosa / Q000187:drug effects; D006801:Humans; D008297:Male; D012811:Sigmoid Neoplasms / Q000628:therapy; D013272:Stomach Diseases / Q000139:chemically induced*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab